Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-01
2011-03-01
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S772000, C514S773000, C514S777000, C530S345000, C530S402000, C536S123100
Reexamination Certificate
active
07897563
ABSTRACT:
The invention relates to the use of oligomers and polymers capable of rendering insoluble drugs soluble, protecting unstable drugs, and facilitating the delivery of drugs to their site of action. This invention further relates to processes for the preparation of such oligomers and polymers, and to compositions containing them. In some instances, oligomers, polymers, and/or mixtures thereof can be used to protect a protein drug. Such structures can include at least one recognition element covalently attached to a hydrophilic element, wherein said recognition element or elements interact noncovalently with the protein drug to form a complex in which said protein drug is protected from degradation, recognition by the immune system, and/or renal excretion.
REFERENCES:
patent: 4002531 (1977-01-01), Royer
patent: 4179337 (1979-12-01), Davis et al.
patent: 4698387 (1987-10-01), Schmidt et al.
patent: 5622699 (1997-04-01), Rusoslahti et al.
patent: 5650398 (1997-07-01), Kensil et al.
patent: 5804604 (1998-09-01), Frankel et al.
patent: 5807746 (1998-09-01), Lin et al.
patent: 5942634 (1999-08-01), Siegel et al.
patent: 6143917 (2000-11-01), Harada et al.
patent: 6322805 (2001-11-01), Kim et al.
patent: 6365146 (2002-04-01), Uhrich
patent: 6410057 (2002-06-01), Kweon-Choi et al.
patent: 6429200 (2002-08-01), Monahan et al.
patent: 6491903 (2002-12-01), Forster et al.
patent: 6492560 (2002-12-01), Wilbur et al.
patent: 6521736 (2003-02-01), Watterson et al.
patent: 7482018 (2009-01-01), Soane et al.
patent: 2001/0004454 (2001-06-01), Wedeking et al.
patent: 2001/0021703 (2001-09-01), Kosak
patent: 2002/0012680 (2002-01-01), Patel et al.
patent: 2002/0098999 (2002-07-01), Gallop et al.
patent: 2003/0176335 (2003-09-01), Zhang et al.
patent: 2006/0148728 (2006-07-01), Lutz et al.
patent: 1 538 166 (2005-06-01), None
patent: 2001226294 (2001-08-01), None
patent: WO-9710849 (1997-03-01), None
patent: WO 99/19276 (1999-04-01), None
patent: WO 99/33940 (1999-07-01), None
patent: WO 99/65467 (1999-12-01), None
patent: WO 01/09163 (2001-02-01), None
patent: WO 01/47562 (2001-07-01), None
patent: WO 01/52826 (2001-07-01), None
patent: WO-0152826 (2001-07-01), None
patent: WO 01/62297 (2001-08-01), None
patent: WO-0185216 (2001-11-01), None
patent: WO-0187345 (2001-11-01), None
patent: WO 02/15877 (2002-02-01), None
patent: WO 02/19963 (2002-03-01), None
patent: WO 02/20033 (2002-03-01), None
patent: WO 02/49676 (2002-06-01), None
patent: WO 02/069930 (2002-09-01), None
Finkelman et al. Anti-Cytokine Antibodies as Carrier Proteins. The Journal of Immunology. Aug. 1, 1993, vol. 151, No. 3, pp. 1235-1244.
Yokoyama, M. et al., “Preparation of Micelle-Forming Polymer-Drug Conjugates,” Bioconjugate Chem. 3(4):295-301 (1992).
Anderson et al., “Folic Acid-PEO-Labeled Liposomes to improve Gastrointestinal Absorption of encapsulated Agents,” J. Controlled Release 60:189-98 (1999).
Anderson, KE et al., “Formulation and Evaluation of a Folic Acid Receptor-Targeted Oral Vancomycin Lipsomal Dosage Form,” Pharm. Res. 18(3):316-22 (2001).
Barron, A et al., “Bioinspired Polymeric Materials: In-Between Proteins and Plastics,” Current Opinion in Chem. Bio. 3:681-87 (1999).
Belcheva, N et al., “Synthesis and Biological Activity of Polyethylene Glycol-Mouse Nerve Growth Factor Conjugate,” Bioconjugate 10:932-37 (1999).
Burbaum, J et al., New Technologies for High-Throughput Screening, Current Opinion in Chem. Bio. 1:72-78 (1997).
Byk G et al., Synthesis, Activity and Structure—Activity Relationship Studies of Novel Cationic Lipids for DNA Transfer, J. Med. Chem. 41:224-35 (1998).
Craig, D et al., “Administration of Emulsions to the Gastrointestinal Tract,” Pharmaceutical Emulsions and Suspensions/Gilberte Marti-Mestres, New York : Marcel Dekker Inc. part 2, p. 323-60 (2000).
CRC Handbook of Chemistry and Physics, 79thed., Lide ed., pp. 16-42-16-46, CRC Press (1998).
Desai, M et al., “Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size,” Pharma. Res. 13(12):1838-45 (1996).
Dodane, V et al., “Effect of Chitosan an Epithelial Permeability and Structure,” Intl J. Pharma. 182:21-32 (1999).
Fahr, F et al., “Permeation Enhancement of Octreotide by Specific Bile Salts in rats and Human Subjects: in Vitro, In Vivo Correlations,” British J. Pharmacology 117:217-23 (1996).
Florence, AT et al., “Oral Uptake and Translocation of a Polylysine Dendrimer with a Lipid Surface,” J. Controlled Release 65:253-59 (2000).
Flitsch, S et al., “Chemical and Enzymatic Synthesis of Glycopolymers,” Current opinion in Chemical Bio. 4:619-25 (2000).
Fukase, K. et al., “Combinatorial and Solid-Phase Methods in Oligosaccharide Synthesis,” 2:1621-60 (2001).
Futaki, S. et al., “Arginine-Rich Peptides,” J. Bio. Chem. 276(8):5836-40 (2001).
Gharat, L. et al., “Targeted Drug Delivery Systems 6: Intracellular Bioreductive Activation, Uptake and Transport of an Anticancer Drug Delivery System Across Intestinal Caco-2 Cell Monolayers,” Intl J. Pharma. 219:1-10 (2001).
Gonzales, L et al., “Buried Polar Residues and Structural Spcificity in the GCN4 Leucine Zipper,” Nature Structural Bio. 3(12):1011-18 (1996).
Guichard, G. et al., “Solid-Phase Synthesis of Pseudopeptides and Oligomeric Peptide Backbone Mimetics,” Mercel Dekker Inc. p. 649-703 (2000).
Hussain, N., “Ligand-Mediated Tissue Specific Drug delivery,” Advanced Drug Delivery Reviews 43:95-100 (2000).
Kast, C et al., “Thiolated Polymers—Thiomers: Development and in Vitro Evaluation of Chitosan-Thioglycolic Acid Conjugates,” Biomaterials 22:2345-52 (2001).
Koenig, H et al., “Polyamines and Ca2 Mediate Hypersmolal Opening of the Blood-Brain Barrier: In Vitro Studies in Isolated Rat Cerebral Capillaries,” J Neurochemistry 52(4):1135-42 (1989).
Koenig, H et al., “Polyamines Mediate the reversible Opening of the Blood-Brain Barrier by the Intracarotid Infusion of Hyperosmolal Mannitol,” Brain Research 483:110-16 (1989).
Kotze, A et al., “N-Trimethyl Chitosan Chloride as a Potential Absorbtion Enhancer Across Mucosal Surfaces: In Vito Evaluation in Intestinal Epithelial Cells (Caco-2)”, Pharmaceutical Research 14(9):1197-1202 (1997).
Kramer, W et al., “Intestinal Absorption of Peptides by Coupling to Bite Acids,” J. Biological Chem. 269(14):10621-27 (1994).
Kwon, G. et al., “Enhanced Tumor Accumulation and Prolonged Circulation Times of Micelle-Forming Poly(ethulene oxide-aspartate) Block Copolymer-Adriamycin Conjugates,” J. Controlled Release 29:17-23 (1994).
Lavasanifar, A. et al., “Poly(ethylene oxide)-block-poly(L-amino acid) Micelles for Drug Delivery,” Adv. Drug Delivery Rev. 54:169-90 (2002).
Lemieux, G et al., “Chemoselective Ligation Reactions with Proteins, Oligosaccharides and cells,” Trends Biotech. 16(12):506-13 (1998).
MacGregor, K. et al., “Influence of Lipolysis on Drug Absorption from the Gastro-Intestinal Tract,” Advanced Drug Delivery Rev. 25:33-48 (1997).
Matsumoto, H. et al., “Controlled Drug Release: New water-soluble Prodrugs of an HIV Protease Inhibitor,” Bioorganic & Medicinal Chem. Lett, 11:605-09 (2001).
Mitchell, DJ et al., “Polyarginine Enters Cells More Efficiently than other Polycationic Homopolymers,” J. Peptide Res. 56:318-25 (2000).
Nakada, y. et al., “the Effect of additives on the Oral Mucosal Absorption of human Calcitonin in rats,” J. Pharmacobio-Dyn 11:395-401 (1988).
Nilsson, F et al., “The Use of Phage Display for the Development of Tumour Targeting Agents,” Adv. Drug Delivery Rev. 43:165-96 (2000).
Norbeck, D. et al., A Novel Prodrug of an Impermeant Inhibitor of 3-Deoxy-D-manno-2-octulosonate Cytidylytransferease has Antibacterial Activity, J. Med. Chem. 32:625-29 (1989).
Seeberger, P. et al., “S
Soane David S.
Suich Daniel J.
Elmore Carolyn S.
Elmore Patent Law Group P.C.
Hoda Mahreen Chaudhry
Russel Jeffrey E
Soane Family Trust
LandOfFree
Use of oligomers and polymers for drug solubilization,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of oligomers and polymers for drug solubilization,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of oligomers and polymers for drug solubilization,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2685473